Skip to content

gosset abstracts Added 16 November 2026. Search conference abstracts across meetings. Needs CLI 0.5.27 or later. ​

Search about 1.5 million conference abstracts from the meetings Gosset covers: oncology (ASCO, ESMO, ESMO Asia, AACR, SABCS, WCLC, SITC), haematology (ASH, EHA), immunology and dermatology (EULAR, ACR, AAD, EADV), cardiometabolic (ADA, ESC, EASL, DDW), respiratory (ATS, ERS), neurology (AAN) and gene therapy (ASGCT). One row is one presentation (abstract, poster, oral or late-breaker) at one edition of a meeting.

Use it to answer questions like:

  • Where has dostarlimab been presented, at any meeting?
  • What did ASCO 2025 show in non-small cell lung cancer?
  • Which abstracts report on trial NCT04784715?
bash
gosset abstracts [SEARCH] [filters] [output flags]

SEARCH (optional) is free text over the abstract.

Needs CLI 0.5.27 or later

gosset abstracts arrived in 0.5.27. Check with gosset version, and upgrade with:

bash
pip install -U gosset

An older CLI answers invalid choice: 'abstracts'.

Filters ​

FlagAcceptsExample
SEARCHfree textgosset abstracts "overall survival" --conference "ESMO 2025"
--drugdrug name or id. Matches abstracts from every meeting--drug dostarlimab
--diseasedisease name or id. Includes narrower diseases--disease "non-small cell lung cancer"
--targettarget name or id of the primary drug--target HER2
--modalitymodality name or id of the primary drug--modality ADC
--companydeveloper of the primary drug, name or id--company AstraZeneca
--conferencea meeting series (every edition), a list, or one edition--conference ASCO · --conference ASCO,ESMO · --conference "ESMO 2025"
--yearedition year, or a list--year 2025 · --year 2024,2025
--ncttrial registry id(s) the abstract is linked to--nct NCT04784715
--phasefurthest phase the primary drug has reached in any indication--phase 3
--min-impactminimum Gosset impact score, 0 to 10--min-impact 8
--annotation-levelannotated or link_only (see below)--annotation-level annotated
--since / --untilpresentation date YYYY-MM-DD--since 2025-10-01

Default sort: newest presentation first. You can also sort on impact, title and edition, for example --sort=-impact.

Three more filters have no flag of their own. Pass them with --where:

ConditionMeaning
--where trial_link_source=reported_in_abstractwith --nct: only abstracts that state the trial id themselves
--where trial_link_source=adjudicatedwith --nct: only links Gosset's trial matcher and a reviewer confirmed
--where is_drug=falsepresentations that are not about a drug (epidemiology, devices, basic science)

--phase is the drug's phase, not the study's

--phase 3 finds abstracts whose primary drug has reached Phase 3 somewhere. A Phase 1 dose-escalation poster for that drug matches too. To find a particular study, use --nct or free text.

Examples ​

Every meeting that presented a drug ​

--drug searches across meetings. Narrow it with --conference or --year:

bash
gosset abstracts --drug dostarlimab --conference ESMO --fields edition,title --table
edition    title
---------  ------------------------------------------------------------
ESMO 2026  LBA46 - Niraparib and dostarlimab plus radiotherapy (RT) in
ESMO 2026  LBA87 - Clinical complete response with dostarlimab monother
ESMO 2026  3548TiP - PRODIGE 90 (PREDIR-NEOREC): Neoadjuvant dostarlima
ESMO 2026  1345TiP - RODEO: pReOperative dostarlimab and novel therapie
…

… showing 25 of 46 total

Drop --conference ESMO to get every meeting (gosset abstracts --drug dostarlimab). A drug search across all meetings can take longer than the other examples on this page.

One conference edition ​

bash
gosset abstracts --conference ASCO --year 2025 --disease "non-small cell lung cancer" --limit 5 --table

--conference "ASCO 2025" is the same as --conference ASCO --year 2025. A series name on its own (--conference ESMO) covers every edition, and a list (--conference ASCO,ESMO --year 2024,2025) covers each combination.

bash
# HER2 abstracts at ESMO 2025
gosset abstracts --conference "ESMO 2025" --target HER2 --limit 5 \
  --fields edition,title,drug,developers --table
edition    title                                                         drug                    developers
---------  ------------------------------------------------------------  ----------------------  ---------------------------
ESMO 2025  536MO - SHR-A1811 plus pertuzumab in human epidermal growth   trastuzumab rezetecan   Jiangsu Hengrui Medicine
ESMO 2025  737MO - Trastuzumab deruxtecan (T-DXd) in patients (pts) wit  trastuzumab deruxtecan  Daiichi Sankyo, AstraZeneca
ESMO 2025  291O - DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan   trastuzumab deruxtecan  Daiichi Sankyo, AstraZeneca
…

… showing 5 of 95 total

Abstracts linked to a trial ​

bash
gosset abstracts --nct NCT04784715 --fields edition,title,trial_ids --table
edition         title                                                         trial_ids
--------------  ------------------------------------------------------------  ------------------------
ESMO 2026       LBA49 - A DESTINY-Breast09 (DB-)09 analysis of trastuzumab d  NCT04784715
ASCO 2026       A DESTINY-Breast09 analysis of treatment duration and clinic  NCT04784715
SABCS 2025      Abstract RF6-07: Trastuzumab deruxtecan (T-DXd) + pertuzumab  NCT04784715
ESMO Asia 2025  88MO Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxa  NCT04784715
ESMO 2025       LBA18 Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs tax  NCT04784715
ASCO 2025       Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane +   NCT04784715
SABCS 2022      Abstract PD18-11: Dose-Expansion Study of Trastuzumab Deruxt  NCT04538742, NCT04784715

That is the DESTINY-Breast09 trial followed from meeting to meeting. Most abstracts name no trial, so a trial search finds the ones that do.

Each link carries its source in trial_links:

bash
gosset abstracts --nct NCT04784715 --limit 1 \
  --fields abstract_id,edition,trial_ids,trial_links,impact,annotation_level
json
[
  {
    "abstract_id": "6adf96cb6965e686e3ad0f3d",
    "edition": "ESMO 2026",
    "trial_ids": ["NCT04784715"],
    "trial_links": [
      {"trial_id": "NCT04784715", "trial_link_source": "reported_in_abstract"},
      {"trial_id": "NCT04784715", "trial_link_source": "adjudicated"}
    ],
    "impact": 8,
    "annotation_level": "annotated"
  }
]
trial_link_sourceMeaning
reported_in_abstractThe abstract states the id itself, in its registration field or as the only id in the text
adjudicatedGosset's trial matcher proposed the link and a reviewer confirmed it

A link with both sources appears once per source. To keep only the ids the abstracts print themselves:

bash
gosset abstracts --nct NCT04784715 --where trial_link_source=reported_in_abstract \
  --fields edition,title,trial_ids --table
edition    title                                                         trial_ids
---------  ------------------------------------------------------------  -----------
ESMO 2026  LBA49 - A DESTINY-Breast09 (DB-)09 analysis of trastuzumab d  NCT04784715
ASCO 2026  A DESTINY-Breast09 analysis of treatment duration and clinic  NCT04784715

Trial ids from registries that issue bare numbers are prefixed with the registry, for example tctr:4765.

Drug class, phase and impact ​

bash
# KRAS G12C abstracts from 2025 whose drug has reached Phase 3
gosset abstracts --target "KRAS G12C" --phase 3 --year 2025 --limit 5 \
  --fields edition,title,drug,latest_phase --table
edition    title                                                         drug        latest_phase
---------  ------------------------------------------------------------  ----------  ------------
ESMO 2025  1846MO - Intracranial efficacy of olomorasib, a second-gener  olomorasib  3
ESMO 2025  927MO - Single-agent divarasib experience in patients with K  divarasib   3
WCLC 2025  OA08.02 Efficacy and Safety of 1L Olomorasib + Chemoimmunoth  olomorasib  3
…

… showing 5 of 15 total
bash
# PD-1 abstracts at ASCO 2025 with an impact score of 9 or more
gosset abstracts --target PD-1 --conference "ASCO 2025" --min-impact 9 --limit 5 \
  --fields edition,title,drug,impact --table
edition    title                                                         drug           impact
---------  ------------------------------------------------------------  -------------  ------
ASCO 2025  Pembrolizumab plus nab-paclitaxel and platinum as first-line  pembrolizumab  9
ASCO 2025  Node-sparing modified short-course radiotherapy combined wit  tislelizumab   9
…

… showing 5 of 73 total
bash
# A company's abstracts at one meeting
gosset abstracts --company AstraZeneca --conference ESMO --year 2025 --limit 3 \
  --fields edition,title,drug --table

Free text and dates ​

bash
gosset abstracts "overall survival" --conference "ESMO 2025" --limit 3 --fields edition,title --table
gosset abstracts --conference ESMO --since 2025-10-01 --until 2025-10-31 --limit 3 --fields date,edition,title --table

Free text is fastest with a conference or year filter alongside it.

The whole set, as JSON ​

bash
gosset abstracts --nct NCT04784715 --all --fields edition,title > db09_abstracts.json

--all pages for you and returns one array (7 abstracts here). It refuses sets above 10,000 rows, so add filters first.

Every abstract has an annotation_level:

ValueWhat it means
annotatedFully annotated: drug, disease, target and developer are extracted from the abstract
link_onlyBack catalogue, mostly 2004 to 2024. Linked only to drugs, diseases and companies already in Gosset, so its links are thinner
bash
gosset abstracts --conference ASCO --year 2015 --annotation-level link_only --limit 3 \
  --fields edition,title,drug,annotation_level --table
edition    title                                                         drug         annotation_level
---------  ------------------------------------------------------------  -----------  ----------------
ASCO 2015  Ibrutinib combined with bendamustine and rituximab (BR) in p  ibrutinib    link_only
ASCO 2015  Phase II study of daratumumab (DARA) monotherapy in patients  daratumumab  link_only
ASCO 2015  Primary results, NRG Oncology/NSABP B-35: A clinical trial o  anastrozole  link_only

… showing 3 of 4879 total

Use --annotation-level annotated when you count or compare, so older, thinner rows don't skew the result.

Useful fields ​

Run gosset schema abstracts for the full list of 33 fields. The ones you'll use most:

FieldWhat it holds
abstract_idStable Gosset id for the presentation
conference, conference_year, editionMeeting series, year, and both as one label (ASCO 2025)
datePresentation or publication date. Some meetings publish only their start date
title, authors, affiliations, url, doiAs published by the meeting
abstract_number, poster_number, session_type, session_titleWhere it sat in the programme
bodyFull abstract text, where the meeting site publishes it
trial_registration, trial_ids, trial_linksThe registration statement as printed, and the linked trials
drug, other_drugs, developersPrimary drug, other drugs named, developers of the primary drug
diseases, targets, target_classes, modalities, modality_classesWhat the abstract is about
latest_phaseFurthest phase the primary drug has reached in any indication, today
impact, impact_commentGosset impact score (0 to 10) for abstracts reporting clinical results, with a one-line reason
endpoints, summaryEndpoints reported, and structured findings (population, key results) where available
annotation_levelannotated or link_only

--table shows date, edition, title, drug, developers and trial ids. Add --fields to pick your own columns.

Piping to jq ​

bash
# Endpoints and the impact rationale for the latest DESTINY-Breast09 abstract
gosset abstracts --nct NCT04784715 --limit 1 --fields title,endpoints,impact_comment \
  | jq '.[0] | {endpoints, impact_comment}'

From Python ​

python
from gosset import GossetClient

client = GossetClient()
res = client.query(
    "abstracts",
    where={"and": [
        {"field": "trial", "value": "NCT04784715"},
        {"field": "trial_link_source", "value": "reported_in_abstract"},
    ]},
    fields=["edition", "title", "trial_ids"],
)
print(res["total"], [r["edition"] for r in res["results"]])

Gosset Documentation